![Transparency Market Researchが調査・発行した産業分析レポートです。世界の多形性膠芽腫治療（GBM）市場2021年ｰ2028年：治療別（放射線療法、化学療法（テモゾロミド、ベバシズマブ、カルムスチン、その他）、その他）、エンドユーザー別 / Glioblastoma Multiforme Treatment (GBM) Market (Treatment: Radiation Therapy, Chemotherapy [Temozolomide, Bevacizumab, Carmustine, and Other Types of Chemotherapy], and Other Treatments; and End-user: Hospitals, Ambulatory Surgical Centers, and Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028 / MRC2205A107資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/99x123xreport-contents-61.gif.pagespeed.ic.-R1hplx-d-.jpg) | • レポートコード：MRC2205A107 • 出版社/出版日：Transparency Market Research / 2022年4月30日 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、世界の多形性膠芽腫治療（GBM）市場について調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療別（放射線治療、化学療法、その他）分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の多形性膠芽腫治療（GBM）市場規模：治療別（放射線治療、化学療法、その他） ・世界の多形性膠芽腫治療（GBM）市場規模：エンドユーザー別 ・世界の多形性膠芽腫治療（GBM）市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Glioblastoma Multiforme Treatment (GBM) Market – Scope of Report
TMR’s report on the global glioblastoma multiforme treatment (GBM) market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global glioblastoma multiforme treatment (GBM) market for the period 2017–2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global glioblastoma multiforme treatment (GBM) market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global glioblastoma multiforme treatment (GBM) market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global glioblastoma multiforme treatment (GBM) market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global glioblastoma multiforme treatment (GBM) market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global glioblastoma multiforme treatment (GBM) market.
The report delves into the competitive landscape of the global glioblastoma multiforme treatment (GBM) market. Key players operating in the global glioblastoma multiforme treatment (GBM) market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global glioblastoma multiforme treatment (GBM) market that have been profiled in this report.
Key Questions Answered in Glioblastoma Multiforme Treatment (GBM) Market Report
What is the scope of growth of product companies in the global glioblastoma multiforme treatment (GBM) market?
What will be the Y-o-Y growth of the global glioblastoma multiforme treatment (GBM) market between 2017 and 2028?
What is the influence of changing trends in technologies on the global glioblastoma multiforme treatment (GBM) market?
Will North America be the most profitable market for glioblastoma multiforme treatment (GBM) providers?
Which factors are anticipated to hamper the growth of the global glioblastoma multiforme treatment (GBM) market during the forecast period?
Which are the leading companies in the global glioblastoma multiforme treatment (GBM) market?
Research Methodology
TMR has utilized a unique research methodology to conduct comprehensive research on the growth of the global glioblastoma multiforme treatment (GBM) market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary methods referred to by analysts during the production of the global glioblastoma multiforme treatment (GBM) market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the glioblastoma multiforme treatment (GBM) market as primary methods.
These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the glioblastoma multiforme treatment (GBM) market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global glioblastoma multiforme treatment (GBM) market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global glioblastoma multiforme treatment (GBM) market more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Glioblastoma Multiforme Treatment (GBM) Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, 2017–2028
5. Key Insights
5.1. Regulatory Scenario, by Region/globally
5.2. Key Mergers & Acquisitions
5.3. Technological Advancements
5.4. COVID-19 Pandemics Impact on Industry
6. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2028
6.3.1. Radiation Therapy
6.3.2. Chemotherapy
6.3.2.1. Temozolomide
6.3.2.2. Bevacizumab
6.3.2.3. Carmustine
6.3.2.4. Other Types of Chemotherapy
6.3.3. Other Treatments
6.4. Market Attractiveness Analysis, by Treatment
7. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2028
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centers
7.3.3. Clinics
7.4. Market Attractiveness Analysis, By End-user
8. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, By Country/Region
9. North America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment, 2017–2028
9.2.1. Radiation Therapy
9.2.2. Chemotherapy
9.2.2.1. Temozolomide
9.2.2.2. Bevacizumab
9.2.2.3. Carmustine
9.2.2.4. Other Types of Chemotherapy
9.3. Market Value Forecast, by End-user, 2017–2028
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Clinics
9.4. Market Value Forecast, by Country, 2017–2028
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment
9.5.2. By End-user
9.5.3. By Country
10. Europe Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment, 2017–2028
10.2.1. Radiation Therapy
10.2.2. Chemotherapy
10.2.3. Temozolomide
10.2.4. Bevacizumab
10.2.5. Carmustine
10.2.6. Other Types of Chemotherapy
10.2.7. Other Treatments
10.3. Market Value Forecast, by End-user, 2017–2028
10.3.1. Hospitals
10.3.2. Ambulatory Surgical Centers
10.3.3. Clinics
10.4. Market Value Forecast, by Country/Sub-region, 2017–2028
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2028
11.2.1. Radiation Therapy
11.2.2. Chemotherapy
11.2.2.1. Temozolomide
11.2.2.2. Bevacizumab
11.2.2.3. Carmustine
11.2.2.4. Other Types of Chemotherapy
11.2.3. Other Treatments
11.3. Market Value Forecast, by End-user, 2017–2028
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Clinics
11.4. Market Value Forecast, by Country/Sub-region, 2017–2028
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment
11.5.2. By Drug Class
11.5.3. By End-user
11.5.4. By Country/Sub-region
12. Latin America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2028
12.2.1. Radiation Therapy
12.2.2. Chemotherapy
12.2.2.1. Temozolomide
12.2.2.2. Bevacizumab
12.2.2.3. Carmustine
12.2.2.4. Other Types of Chemotherapy
12.2.3. Other Treatments
12.3. Market Value Forecast, by End-user, 2017–2028
12.3.1. Hospitals
12.3.2. Ambulatory Surgical Centers
12.3.3. Clinics
12.4. Market Value Forecast, by Country/Sub-region, 2017–2028
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment
12.5.2. By Drug Class
12.5.3. By End-user
12.5.4. By Country/Sub-region
13. Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2028
13.2.1. Radiation Therapy
13.2.2. Chemotherapy
13.2.2.1. Temozolomide
13.2.2.2. Bevacizumab
13.2.2.3. Carmustine
13.2.2.4. Other Types of Chemotherapy
13.2.3. Other Treatments
13.3. Market Value Forecast, by End-user, 2017–2028
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers
13.3.3. Clinics
13.4. Market Value Forecast, by Country/Sub-region, 2017–2028
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment
13.5.2. By Drug Class
13.5.3. By End-user
13.5.4. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. Merck & Co., Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Analysis
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. F. Hoffmann-La Roche Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Analysis
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Pfizer Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Analysis
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Amgen, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Analysis
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Analysis
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Sun Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Analysis
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Arbor Pharmaceuticals, LLC
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Analysis
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Amneal Pharmaceuticals
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Analysis
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Karyopharm Therapeutics, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Analysis
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Analysis
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis